DLI was associated with another curative treatment in 34.6% of patients: tyrosine kinase inhibitor for CML or ALL (n = 10), hypomethylating agents for myelodysplasia or AML (n = 24), immunomodulatory drug for myeloma (n = 15), anti-CD20 monoclonal antibody for non-Hodgkin lymphoma (n = 1), anti-CD33 or anti-CD30 monoclonal antibody-drug conjugates for AML and Hodgkin lymphoma, respectively (n = 1 each), and JAK2 inhibitor for osteomyelofibrosis (n = 1) or chemotherapy (n = 6). The gene discussed is JAK2; the disease is plasma cell myeloma.